Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocidib and Docetaxel in Refractory Metastatic Pancreatic Cancer
NCT00331682Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alvocidib in pancreatic cancer (PC), sponsored by National Cancer Institute. Started Mar 2006; status: completed.
02
Drugs
alvocidib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00331682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331682.